this post was submitted on 09 Apr 2025
12 points (87.5% liked)

Public Health

617 readers
19 users here now

For issues concerning:

🩺 This community has a broader scope so please feel free to discuss. When it may not be clear, leave a comment talking about why something is important.

Related Communities

See the pinned post in the Medical Community Hub for links and descriptions. link ([email protected])

Rules

Given the inherent intersection that these topics have with politics, we encourage thoughtful discussions while also adhering to the mander.xyz instance guidelines.

Try to focus on the scientific aspects and refrain from making overly partisan or inflammatory content

Our aim is to foster a respectful environment where we can delve into the scientific foundations of these topics. Thank you!

founded 2 years ago
MODERATORS
[email protected]
[email protected]
12
How Ozempic and Similar Drugs Are Quietly Rewriting America’s Eating Habits (gizmodo.com)
submitted 2 weeks ago by [email protected] to c/[email protected]
3 comments fedilink hide all child comments
you are viewing a single comment's thread
view the rest of the comments
[–] [email protected] 2 points 1 week ago (1 children)

the glp-1 antagonists mimic low grade ketosis

Do you have a reference for that?

[–] [email protected] 1 points 1 week ago* (last edited 1 week ago)

https://doi.org/10.1038/s41366-025-01749-x

TLDR: GLP-1 and SGLT-2 drugs have been associated with EKA in the literature; Treating physicians need to be aware of ketone levels of their patients, or at least keep the EKA as a possible differential diagnosis. This hints at a underlying mechanism of benefit between ketogenic metabolism and these drugs.

https://doi.org/10.1016/j.clinthera.2016.11.002

SGLT2 inhibitors have been associated with increases in ketone-associated adverse events.

these data suggest a causal relationship between SGLT2 inhibitors and an asymptomatic rise in ketone bodies